What are your areas of concern
Hepatol Res 45(3):269278 Errafii K, Khalifa O, Al-Akl NS, Arredouani A (2022) Comparative transcriptome analysis reveals that Exendin-4 improves steatosis in HepG2 cells by modulating signaling pathways related to lipid metabolism
It means maintenance is a medical strategy, not a finish line
Some drugs for the treatment of T2DM may cause systemic side-effects such as hypoglycemia, and the long-term administration of insulin could promote brain insulin resistance (17)
Protocol 5: neurological recovery support Goal: Support recovery from TBI, stroke, or other neurological injury Primary peptide: Cerebrolysin 10-20ml IM daily for 10-20 days (requires medical supervision) Alternatively: Semax 600-900mcg daily if Cerebrolysin unavailable Supporting peptide: BPC-157 500mcg twice daily for tissue healing Duration: Acute phase treatment, may repeat cycles as recovery progresses Considerations: Neurological injury recovery should involve medical supervision
Novo Nordisk and Eli Lilly dominate this share due to their strong GLP1 and dualagonist drug portfolios, while Takeda, Merck, and Sanofi maintain a solid presence through ongoing R&D investments and expansion in metabolicdisease therapeutics
